| PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
2022-1-07 |
2023-7-13 |
|
| Fixed dose combinations of chs-131 and a sglt-2 inhibitor |
2021-9-01 |
2022-3-10 |
|
| Fixed dose combinations of chs-131 and a ppar agonist |
2021-9-01 |
2022-3-10 |
|
| Fixed dose combinations of chs-131 and a dpp-4 inhibitor |
2021-9-01 |
2022-3-10 |
|
| Fixed dose combinations of chs-131 and a fxr agonist |
2021-9-01 |
2022-3-10 |
|
| Fixed dose combinations of chs-131 and a thyroid receptor beta agonist |
2021-9-01 |
2022-3-10 |
|
| Process for producing, isolating, and purifying modified recombinant proteins |
2021-6-27 |
2021-8-31 |
|
| Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
2021-6-24 |
2021-8-31 |
|
| Method of filling a container with no headspace |
2021-6-17 |
2022-2-10 |
|
| Systems and methods for producing sterile injection devices |
2021-5-21 |
2023-6-29 |
|
| Accurately folded etanercept with high purity and excellent yield |
2021-2-22 |
2021-7-08 |
|
| Stable aqueous formulations of adalimumab |
2020-10-21 |
2021-2-18 |
|
| Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
2020-10-14 |
2022-8-24 |
|
| Methods for producing ranibizumab |
2020-10-09 |
2021-4-15 |
|
| Methods of purifying ranibizumab or a ranibizumab variant |
2020-10-09 |
2021-4-15 |
|
| Control mechanism for priming an injection device |
2020-10-02 |
2022-10-27 |
|
| Etanercept formulations exhibiting marked reduction in sub-visible particles |
2020-9-28 |
2021-1-14 |
|
| Etanercept formulations stabilized with xylitol |
2020-9-14 |
2020-12-31 |
|
| Stable aqueous formulations of aflibercept |
2020-9-10 |
2021-3-18 |
|
| Perfusion media |
2020-7-22 |
2020-8-06 |
|
| Methods for the treatment of nonalcoholic fatty liver disease and/or … |
2020-6-25 |
2020-12-10 |
|
| Compositions and methods to treat cancer |
2020-5-26 |
2022-6-30 |
|
| Method of producing a recombinant protein |
2020-5-01 |
2022-6-23 |
|
| Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
2019-12-27 |
2020-10-08 |
|
| Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
2019-12-27 |
2022-6-23 |
|
| Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
2019-12-27 |
2020-10-08 |
|
| Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
2019-12-27 |
2020-10-08 |
|
| Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
2019-12-27 |
2022-2-09 |
|
| Protein production method |
2019-12-19 |
2020-5-14 |
|
| Methods for producing recombinant proteins |
2019-12-06 |
2020-11-01 |
|
| Ppargamma agonist for treatment of progressive supranuclear palsy |
2019-9-26 |
2019-11-28 |
|
| Stable aqueous formulations of aflibercept |
2019-9-10 |
2020-8-06 |
|
| Methods for making recombinant proteins |
2019-9-09 |
2022-7-26 |
2022-7-26 |
| Ppargamma agonist for the treatment of huntington's disease |
2019-7-11 |
2019-9-26 |
|
| Etanercept Formulations Stabilized with Sodium Chloride |
2019-6-28 |
2019-11-14 |
|
| Methods of treating subjects with an elevated neurofilament light chain level |
2019-4-02 |
2020-1-16 |
|
| Stable aqueous formulations of aflibercept |
2019-3-08 |
2021-1-13 |
|
| Method of reducing immunogenicity of drug products |
2017-10-25 |
2018-2-15 |
|
| PPAR-gamma AGONIST FOR TREATMENT OF BLOOD CANCERS |
2017-8-18 |
2021-12-09 |
|
| Antidiabetic Solid Pharmaceutical Compositions |
2017-6-12 |
2017-9-28 |
|
| PPARĪ³ agonists for treatment of multiple sclerosis |
2017-1-10 |
2018-1-16 |
2018-1-16 |
| High concentration formulations of adalimumab |
2016-10-28 |
2022-1-25 |
2022-1-25 |
| Stable protein compositions and methods of their use |
2016-10-28 |
2023-2-21 |
2023-2-21 |
| Stable Aqueous Formulations of Natalizumab |
2016-7-18 |
2021-10-21 |
|
| STABILIZED FORMULATIONS OF ETANERCEPT |
2013-7-08 |
2014-2-28 |
|